Vera (VERA) Q2 Net Loss Widens 127%

Vera Therapeutics (VERA 1.37%), a biotechnology company developing treatments for serious immunologic diseases, released results for the quarter on August 5, 2025. The most notable news was its widening net loss to $76.5 million, or $1.20 per share (GAAP), compared to analyst expectations for a GAAP loss of $0.82 per share. While the company posted headline revenue of $76.5 million (GAAP). Results show accelerated spending as the company moves closer to a planned regulatory filing for its lead drug candidat ...